Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
National Inst. of Pharma Education and Research (NIPER) VEGFR-2 compound 8u: sourced facts only. name: "Further, VEGFR inhibition assay revealed that the compound 8u inhibited VEGFR-2 kinase with an IC50 of 1.52 ± 0.08 μM, comparable to the standard drug sunitinib (1.2 ± 0.07 μM)." [PMID:40712230]; target: "Further, VEGFR inhibition assay revealed that the compound 8u inhibited VEGFR-2 kinase with an IC50 of 1.52 ± 0.08 μM, comparable to the standard drug sunitinib (1.2 ± 0.07 μM)." [PMID:40712230]; developer: "Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India." [PMID:40712230]; stage: "Among the synthesized derivatives, compound 8u exhibited potent cytotoxicity against the HepG-2 cell line with an IC50 of 1.88 ± 0.83 μM." [PMID:40712230]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on National Inst. of Pharma Education and Research (NIPER) VEGFR-2 compound 8u.